Literature Highlights

Each month the Steering Committee selects the latest published original articles on immune-mediated inflammatory diseases, focusing on those with data on therapeutic interventions and those that have clinical impact.

October 2025

PsA Literature Highlights - October 2025

more…

Keywords:

Phase 3, PRO/QoL, Radiographic, Secukinumab, Skin, Guselkumab, IL-23, Phase 3, Dactylitis, Enthesitis, TNF, Outcomes, Persistence, Real-World, Safety

AxSpA Literature Highlights - October 2025

more…

Keywords:

Adalimumab, Ankylosing spondylitis, Anti-tnf therapy, Cardiovascular risk, Carotid intima-media thickness, Dosing, Inflammation, Lipid profile, Radiographic, Real-World.

RA Literature Highlights - October 2025

more…

Keywords:

Baricitinib, sarilumab, safety, real-world, drug retention, monotherapy, combination

Literature review thumbnail: Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

In this first global clinical study of a nanobody in inflammatory arthritis, sonelokimab, an
IL-17A- and IL-17F-inhibiting nanobody demonstrated strong efficacy across multiple domains including high-hurdle composite joint and skin responses. McInnes et al. reported on the Phase 2, randomized, double-blind, PBO-controlled ARGO trial which evaluated the efficacy and safety of sonelokimab in patients with active PsA.

more…